Supportive Care | Specialty

Clinical and Practical Data On Use of Retinoic Acid and Arsenic Trioxide in APL

January 17th 2017

Changes to the European Guidelines for Treatment of APL

January 17th 2017

Timely Diagnosis of Acute Promyelocytic Leukemia

January 17th 2017

Dr. Puzanov on Management of Adverse Events in Melanoma

December 30th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

High-User Focus Trims Oncology Tab

December 13th 2016

It was 15 years ago that Jeffrey Brenner, MD, hypothesized that patients with the highest costs in the Camden, New Jersey, healthcare system received the worst care.

More Evidence That Scalp Cooling Devices Work, Especially During Taxane-Based Chemotherapy

December 9th 2016

Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

November 16th 2016

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Benefits of Genomic Testing in Breast Cancer

October 24th 2016

Types of Genomic Testing

October 24th 2016

Genomic Testing for Risk of Late Recurrence/ASCO Guidelines

October 24th 2016

QOL Analysis of MA.17R and Treatment Decisions

October 24th 2016

Extended Aromatase Inhibitor Risk/Benefit

October 24th 2016

Risk of Early Versus Late Recurrence

October 24th 2016

MA.17R Trial Data Effect on Treatment of ER+ Disease

October 24th 2016

MA.17R Trial Data Results

October 24th 2016

Treatment for Early-Stage ER+ Breast Cancer

October 24th 2016

It's Time to Take Action on Quality Improvement Measures

October 21st 2016

In 2014, under the leadership of UVA Executive Vice President Richard P. Shannon, MD, the Be Safe initiative was developed to deliver the highest-quality of advanced healthcare to patients, and emphasizes 3 main areas.

Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma Treatment

October 6th 2016

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

October 2nd 2016

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Anti-Nausea Benefit Observed With Olanzapine in Patients Receiving HEC Regimen

September 26th 2016

For patients receiving highly emetogenic chemotherapy, olanzapine (Zyprexa) was found to demonstrate a significant improvement in the prevention of nausea when it was added to a standard antiemetic regimen.